8-K Announcements
6Material company update
Mar 24, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Feb 17, 2026·SEC
NRx Pharmaceuticals, Inc.(NRXP)Earnings, Financials & Key Ratios
NRXP•NASDAQ
Price updated Jun 19, 2026
AboutNRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.Show more
- Revenue$1M
- EBITDA-$16M+18.4%
- Net Income-$29M-13.9%
- EPS (Diluted)-1.34+43.9%
- Gross Margin58.78%
- EBITDA Margin-1312.73%
- Operating Margin-1324.41%
- Net Margin-2336.49%
NRXP Key Insights
NRx Pharmaceuticals, Inc. (NRXP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NRXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRXP Price & Volume
NRx Pharmaceuticals, Inc. (NRXP) stock price & volume — 10-year historical chart
Loading chart...
NRXP Growth Metrics
NRx Pharmaceuticals, Inc. (NRXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM38.91%
Return on Capital
10 Years-186.53%
5 Years-371.63%
3 Years-
Last Year-
NRXP Recent Earnings
NRx Pharmaceuticals, Inc. (NRXP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.04+20.0%
$0.05
Rev
$1M-94.5%
$19M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.19+311.1%
$0.09
Rev
$983,000-86.9%
$8M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.18-63.6%
$0.11
Rev
$242,000-96.8%
$8M
Q2 2025
May 15, 2025Metric
Actual
Est
EPS
$0.34-13.3%
$0.30
Rev
$2M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.04vs $0.05+20.0% | $1Mvs $19M-94.5% |
| Q2 2026 | Mar 23, 2026 | $0.19vs $0.09+311.1% | $983,000vs $8M-86.9% |
| Q4 2025 | Nov 14, 2025 | $0.18vs $0.11-63.6% | $242,000vs $8M-96.8% |
| Q2 2025 | May 15, 2025 | $0.34vs $0.30-13.3% | $2M |
Based on last 12 quarters of dataView full earnings history →
NRXP Peer Comparison
NRx Pharmaceuticals, Inc. (NRXP) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 ALTO | 388.01M | 5.02 | 31.38 | -4.9% | 3.16% | 12.53% | 0.40 | |
 INMB | 38.55M | 1.45 | -0.78 | 257.14% | -170.86% | 0.04 | ||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 NRXS | 88.55M | 7.15 | -7.53 | 32.89% | -170.11% | -185.74% | 0.12 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare NRXP vs Peers
NRx Pharmaceuticals, Inc. (NRXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRXP Income Statement
NRx Pharmaceuticals, Inc. (NRXP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23M | 2.29M |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 1.01M | 0 | 2K | 2K | 4K | 5K | 5K | 505K | 1.44M |
COGS % of Revenue | - | - | - | - | - | - | - | - | 41.22% | - |
Gross Profit | 0▲ 0% | -1.01M▲ 0% | 0▲ 100.0% | -2K▲ 0% | -2K▲ 0.0% | -4K▼ 100.0% | -5K▼ 25.0% | -5K▲ 0.0% | 720K▲ 14500.0% | 851K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | 58.78% | 37.11% |
Gross Profit Growth % | - | - | 100% | - | 0% | -100% | -25% | 0% | 14500% | - |
Operating Expenses | 0 | 0 | 713.19K | 22.06M | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M | 18.04M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | 1383.18% | - |
Selling, General & Admin | 0 | 1.01M | 713.19K | 11.43M | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M | 13.76M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | 1066.2% | - |
Research & Development | 0 | 0 | 0 | 10.63M | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M | 4.28M |
R&D % of Revenue | - | - | - | - | - | - | - | - | 308.33% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 106K | 0 |
Operating Income | 0▲ 0% | -1.01M▲ 0% | -713.19K▲ 29.1% | -22.06M▼ 2993.3% | -95.2M▼ 331.5% | -44.34M▲ 53.4% | -27.59M▲ 37.8% | -19.7M▲ 28.6% | -16.22M▲ 17.7% | -17.19M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | -1324.41% | -749.67% |
Operating Income Growth % | - | - | 29.14% | -2993.3% | -331.54% | 53.43% | 37.78% | 28.58% | 17.66% | - |
EBITDA | -105K | 82.41K | 492.63K | -22.06M | -95.2M | -44.33M | -27.58M | -19.7M | -16.08M | -30.73M |
EBITDA Margin % | - | - | - | - | - | - | - | - | -1312.73% | -1340.38% |
EBITDA Growth % | - | 178.49% | 497.77% | -4577.78% | -331.57% | 53.43% | 37.78% | 28.58% | 18.37% | -59.96% |
D&A (Non-Cash Add-back) | 52.52K | 0 | 0 | 2K | 2K | 4K | 5K | 5K | 143K | 306K |
EBIT | -105K | 82.41K | 492.63K | -51.72M | -93.05M | -39.75M | -30.03M | -24.05M | -27.95M | -31.04M |
Net Interest Income | 0 | 0 | 1.21M | -55.94K | -17.98K | 249K | 374K | -1.03M | -659K | -891K |
Interest Income | 0 | 1.09M | 1.21M | 56 | 18 | 249K | 494K | 44K | 12K | 13K |
Interest Expense | 0 | 0 | 0 | 56K | 18K | 0 | 120K | 1.08M | 671K | 904K |
Other Income/Expense | -105K | 1.09M | 1.21M | -29.72M | 2.14M | 4.58M | -2.56M | -5.42M | -12.4M | -7.35M |
Pretax Income | -105K▲ 0% | 82.41K▲ 178.5% | 492.63K▲ 497.8% | -51.78M▼ 10610.3% | -93.06M▼ 79.7% | -39.75M▲ 57.3% | -30.15M▲ 24.2% | -25.13M▲ 16.7% | -28.62M▼ 13.9% | -24.54M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | -2336.49% | -1070.26% |
Income Tax | 0 | 16.31K | 84.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 19.79% | 17.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -105K▲ 0% | 66.1K▲ 163.0% | 408.43K▲ 517.9% | -51.78M▼ 12777.2% | -93.06M▼ 79.7% | -39.75M▲ 57.3% | -30.15M▲ 24.2% | -25.13M▲ 16.7% | -28.62M▼ 13.9% | -24.54M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | -2336.49% | -1070.26% |
Net Income Growth % | - | 162.95% | 517.88% | -12777.17% | -79.74% | 57.28% | 24.16% | 16.66% | -13.91% | -1.79% |
Net Income (Continuing) | -105K | 66.1K | 408.43K | -51.78M | -93.06M | -39.75M | -30.15M | -25.13M | -28.62M | -24.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.12▲ 0% | 0.07▲ 161.8% | 0.80▲ 979.6% | -1.51▼ 288.8% | -7.44▼ 392.7% | -0.60▲ 91.9% | -3.98▼ 563.3% | -2.39▲ 39.9% | -1.34▲ 43.9% | -0.76▲ 0% |
EPS Growth % | - | 161.75% | 979.62% | -288.75% | -392.72% | 91.94% | -563.33% | 39.95% | 43.93% | 38.91% |
EPS (Basic) | -0.12 | 0.07 | 0.80 | -1.51 | -7.44 | -0.60 | -3.98 | -2.39 | -1.34 | - |
Diluted Shares Outstanding | 903.55K | 892.5K | 508.83K | 546.59K | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M | 32.33M |
Basic Shares Outstanding | 903.55K | 892.5K | 508.83K | 546.59K | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M | 32.33M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NRXP Balance Sheet
NRx Pharmaceuticals, Inc. (NRXP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 536.38K | 30.19K | 69.49K | 2.93M | 32.71M | 25.8M | 6.88M | 3.3M | 8.89M | 7.36M |
Cash & Short-Term Investments | 449.37K | 11.08K | 6 | 1.86M | 27.61M | 20.05M | 4.59M | 1.44M | 7.8M | 6.71M |
Cash Only | 449.37K | 11.08K | 6 | 1.86M | 27.61M | 20.05M | 4.59M | 1.44M | 7.8M | 6.71M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 831K | 0 | 7K | 6K | 0 | 161K | 181K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | 47.97 | 23.12 |
Inventory | 0 | 0 | 0 | 214K | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | 39.05K | - | - | - | - | - | - |
Other Current Assets | 87K | 19.11K | 0 | 26K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 69.03M | 70.77M | 32.01M | 11K | 15K | 21K | 431K | 349K | 4.06M | 4.54M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 633K | 936K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 1.94x | 4.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.79M | 1.79M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925K | 879K |
Long-Term Investments | 69.03M | 70.77M | 32.01M | 0 | 0 | 0 | 0 | 0 | 397K | 796K |
Other Non-Current Assets | 0 | 0 | 0 | 11K | 15K | 21K | 431K | 349K | 316K | 535K |
Total Assets | 69.57M▲ 0% | 70.8M▲ 1.8% | 32.07M▼ 54.7% | 2.94M▼ 90.8% | 32.73M▲ 1012.9% | 25.82M▼ 21.1% | 7.32M▼ 71.7% | 3.65M▼ 50.1% | 12.96M▲ 254.9% | 11.9M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.09x | 0.21x |
Asset Growth % | - | 1.77% | -54.69% | -90.83% | 1012.85% | -21.12% | -71.66% | -50.09% | 254.86% | 539.68% |
Total Current Liabilities | 93.17K | 567.41K | 622.44K | 46.16M | 11.92M | 15.59M | 19.05M | 21.86M | 28.58M | 25.18M |
Accounts Payable | 85.67K | 551.1K | 0 | 3.15M | 3.69M | 2.08M | 4.63M | 4.13M | 4.27M | 4.4M |
Days Payables Outstanding | - | 199.85 | - | 575.42K | 672.88K | 189.44K | 338.14K | 301.49K | 3.09K | 1.05K |
Short-Term Debt | 0 | 0 | 0 | 249K | 518K | 7.7M | 9.16M | 1.57M | 316K | 391K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.5K | 0 | 622.44K | 0 | 4.87M | 37K | 4.42M | 10.93M | 23.99M | 20.39M |
Current Ratio | 5.76x | 0.05x | 0.11x | 0.06x | 2.74x | 1.66x | 0.36x | 0.15x | 0.31x | 0.29x |
Quick Ratio | 5.76x | 0.05x | 0.11x | 0.06x | 2.74x | 1.66x | 0.36x | 0.15x | 0.31x | 0.29x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.02K |
Total Non-Current Liabilities | 0 | 690K | 1.95M | 548K | 0 | 2.82M | 0 | 5.01M | 315K | 543K |
Long-Term Debt | 0 | 690K | 1.95M | 548K | 0 | 2.82M | 0 | 5.01M | 315K | 543K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 315K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 93.17K | 1.26M | 2.57M | 46.71M | 11.92M | 18.41M | 19.05M | 26.87M | 28.89M | 25.72M |
Total Debt | 0 | 690K | 1.95M | 797K | 518K | 10.53M | 9.16M | 6.58M | 631K | 934K |
Net Debt | -449.37K | 678.92K | 1.95M | -1.06M | -27.09M | -9.53M | 4.57M | 5.13M | -7.17M | -5.78M |
Debt / Equity | - | 0.01x | 0.07x | - | 0.02x | 1.42x | - | - | - | -0.07x |
Debt / EBITDA | - | 8.37x | 3.96x | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | 8.24x | 3.96x | - | - | - | - | - | - | 0.19x |
Interest Coverage | - | - | - | -923.59x | -5169.17x | - | -250.25x | -22.29x | -41.66x | -34.34x |
Total Equity | 69.47M▲ 0% | 69.54M▲ 0.1% | 29.5M▼ 57.6% | -43.77M▼ 248.4% | 20.81M▲ 147.5% | 7.41M▼ 64.4% | -11.73M▼ 258.4% | -23.22M▼ 97.9% | -15.94M▲ 31.4% | -13.82M▲ 0% |
Equity Growth % | - | 0.1% | -57.58% | -248.37% | 147.53% | -64.39% | -258.36% | -97.93% | 31.37% | -54.03% |
Book Value per Share | 76.89 | 77.91 | 57.98 | -80.08 | 0.44 | 0.11 | -1.55 | -2.21 | -0.74 | -0.43 |
Total Shareholders' Equity | 69.47M | 69.54M | 29.5M | -43.77M | 20.81M | 7.41M | -11.73M | -23.22M | -15.94M | -13.82M |
Common Stock | 64.48M | 64.54M | 24.5M | 43K | 59K | 67K | 84K | 15K | 32K | 33K |
Retained Earnings | -105.03K | -38.93K | 369.5K | -90.18M | -183.24M | -223M | -253.15M | -278.27M | -306.89M | -308.32M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -3K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRXP Cash Flow Statement
NRx Pharmaceuticals, Inc. (NRXP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -135.81K | -473.19K | -792.73K | -2.27M | -37.7M | -39.76M | -21.66M | -10.64M | -14.11M | -14.93M |
Operating CF Margin % | - | - | - | - | - | - | - | - | -1152% | - |
Operating CF Growth % | - | -248.43% | -67.53% | -185.72% | -1564.59% | -5.44% | 45.52% | 50.88% | -32.67% | -217.33% |
Net Income | -105.03K | 66.1K | 408.43K | -51.78M | -93.06M | -39.75M | -30.15M | -25.13M | -28.62M | -24.54M |
Depreciation & Amortization | 0 | 0 | 0 | 2K | 2K | 4K | 5K | 5K | 143K | 306K |
Stock-Based Compensation | 0 | 0 | 0 | 730K | 7.79M | 3.63M | 387K | 486K | 228K | 299K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -115.11K | -1.55M | -1.21M | 45.33M | 52.47M | -4.33M | 2.94M | 8.71M | 12.73M | 7.27M |
Working Capital Changes | -1.33K | 549.63K | 4.66K | 3.45M | -4.9M | 699K | 5.16M | 5.29M | 1.41M | 1.74M |
Change in Receivables | 0 | 0 | 0 | -831K | 831K | 0 | 0 | 0 | 48K | -12K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 85.67K | 465.43K | 0 | 1.18M | -19K | -1.61M | 2.65M | -5.22M | 113K | 51K |
Cash from Investing | -69M | -647.61K | 40.25M | -2K | -7K | -10K | -3K | 0 | -2.81M | -3.02M |
Capital Expenditures | 0 | 0 | 0 | -2K | -7K | -10K | -3K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.38M | -2.38M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -69M | -647.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 69.59M | 682.5K | -39.46M | 3.25M | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M | 19.11M |
Debt Issued (Net) | 0 | 690K | 1.26M | 620K | -1.28M | 9.5M | -3.09M | -1.5M | 7.42M | 3.09M |
Equity Issued (Net) | 69.59M | -7.5K | -40.73M | 2.63M | 36.98M | 22.7M | 9.29M | 5.91M | 15.86M | 16.03M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 70.03M | 0 | -40.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 27.75M | 10K | 0 | 3.07M | 0 | 0 |
Net Change in Cash | 449.37K▲ 0% | -438.3K▼ 197.5% | -11.07K▲ 97.5% | 982K▲ 8968.4% | 25.75M▲ 2521.8% | -7.55M▼ 129.3% | -15.46M▼ 104.7% | -3.15M▲ 79.6% | 6.35M▲ 301.6% | 1.17M▲ 0% |
Free Cash Flow | -135.81K▲ 0% | -473.19K▼ 248.4% | -792.73K▼ 67.5% | -2.27M▼ 186.0% | -37.71M▼ 1563.4% | -39.77M▼ 5.4% | -21.66M▲ 45.5% | -10.64M▲ 50.9% | -14.11M▼ 32.7% | -14.93M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | -1152% | -650.98% |
FCF Growth % | - | -248.43% | -67.53% | -185.97% | -1563.43% | -5.45% | 45.53% | 50.89% | -32.67% | -38.79% |
FCF per Share | -0.15 | -0.53 | -1.56 | -4.15 | -0.80 | -0.60 | -2.86 | -1.01 | -0.66 | -0.46 |
FCF Conversion (FCF/Net Income) | 1.29x | -7.16x | -1.94x | 0.04x | 0.41x | 1.00x | 0.72x | 0.42x | 0.49x | 0.61x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 885K | 374K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRXP Key Ratios
NRx Pharmaceuticals, Inc. (NRXP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 0.1% | 0.82% | - | -447.29% | -281.79% | - | - | - | 107.73% |
Return on Invested Capital (ROIC) | -1.08% | -1.05% | - | - | - | - | - | - | 49.79% |
Gross Margin | - | - | - | - | - | - | - | 58.78% | 37.11% |
Net Margin | - | - | - | - | - | - | - | -2336.49% | -1070.26% |
Debt / Equity | 0.01x | 0.07x | - | 0.02x | 1.42x | - | - | - | -0.07x |
Interest Coverage | - | - | -923.59x | -5169.17x | - | -250.25x | -22.29x | -41.66x | -34.34x |
FCF Conversion | -7.16x | -1.94x | 0.04x | 0.41x | 1.00x | 0.72x | 0.42x | 0.49x | 0.61x |
Related:NRXP Dividend History·NRXP Revenue History·NRXP Price History·NRXP P/E History·NRXP Financial Ratios·NRXP Institutional Holders
NRXP SEC Filings & Documents
NRx Pharmaceuticals, Inc. (NRXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
NRXP Frequently Asked Questions
NRx Pharmaceuticals, Inc. (NRXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NRx Pharmaceuticals, Inc. (NRXP) reported $2.3M in revenue for fiscal year 2025.
NRx Pharmaceuticals, Inc. (NRXP) grew revenue by 0.0% over the past year. Growth has been modest.
NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $24.5M for fiscal year 2025.
Dividend & Returns
NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $14.9M in fiscal year 2025, likely due to heavy capital investments.